Werner Schroth - Concepedia

Author

Werner Schroth

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology ORCID

Also Known As

Dominic Gross, Moritz, R. F.A., Schroth, W., W Schroth, W. S. Schroth, W. SCHROTH, W. Schroth, WERNER SCHROTH, Werner Schroth

434

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Martin Luther University Halle-Wittenberg University of Tübingen German Cancer Research Center Heidelberg University

About

Werner Schroth is an author at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology specializing in chemistry, organic chemistry, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	12	13	315
2	Natural Sciences	11	12	285
3	Medicine	10	10	551
4	Health Sciences	1	1	197
5	Applied Physics	1	1	16

Werner Schroth

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors Martin Filipits, Margaretha Rudas, R. Jakesz, Clinical Cancer Research	2011	703
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen Werner Schroth JAMA	2009	525
Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes Werner Schroth, Lydia Antoniadou, Péter Fritz, Journal of Clinical Oncology	2007	465
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma T E Mürdter, Werner Schroth, L. Bacchus-Gerybadze, Clinical Pharmacology & Therapeutics	2011	267
Speciation and phylogeography in the cosmopolitan marine moon jelly, Aurelia sp Werner Schroth, Gerhard Jarms, Bruno Streit, BMC Evolutionary Biology	2002	227
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer Pilar H. Saladores, Thomas E. Mürdter, Diana Eccles, The Pharmacogenomics Journal Breast OncologyGynecologyPharmacotherapyEndocrine OncologyBody Mass Index	2014	197
Molecular resolution of marine turtle stock composition in fishery bycatch: a case study in the Mediterranean Luc Laurent, Paolo Casale, Mohamed Nejmeddine Bradaï, Molecular Ecology	1998	188
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters Hiltrud Brauch, Werner Schroth, Matthew P. Goetz, Journal of Clinical Oncology Breast OncologyCyp2d6 GenotypeMedicineGeneticsGenetic Epidemiology	2012	101
<i>CYP2D6</i> Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification Werner Schroth, Ute Hamann, Peter A. Fasching, Clinical Cancer Research	2010	87
Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment Reiner Hoppe, Joanna Achinger-Kawecka, Stefan Winter, European Journal of Cancer Breast OncologyTamoxifen TreatmentMedicinePathologyRelapse-free Time	2013	85

Page 1